AVEO gets US FDA approval for Fotivda to treat renal cell carcinoma
AVEO claimed that Fotivda is the first FDA approved therapy for relapsed or refractory advanced renal cell carcinoma…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Mar 21
AVEO claimed that Fotivda is the first FDA approved therapy for relapsed or refractory advanced renal cell carcinoma…
10 Mar 21
Takeda will obtain Maverick’s T-cell engager COBRA platform and its lead development candidates TAK-186 (MVC-101) and TAK-280 (MVC-280)
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Mar 21
Biolojic will receive up to $121m, including potential milestones and a promissory note, along with tiered royalties on…
08 Mar 21
The company claimed that its Yescarta is the first chimeric antigen receptor (CAR) T-cell therapy approved for patients…
05 Mar 21
Novartis will manufacture the mRNA and bulk drug product for up to 50 million doses of the CVnCoV…
04 Mar 21
Exscientia intends to use proceeds from the financing round to further advance AI drug discovery platform and portfolio
04 Mar 21
The expanded approval is based on CROWN trial, which showed that treatment using Lorbrena reduced the risk of…
01 Mar 21
The Covid-19 vaccine has been granted emergency use authorisation after evaluation of safety, effectiveness and manufacturing quality by…
26 Feb 21
Takeda will continue to manufacture and supply the products under the sale to Teijin Pharma
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Feb 21
The Phase 1/2/3 trial evaluates the safety and tolerability of a third dose of BNT162b2 and its effectiveness…